Thor Medical A (TRMED.OL) Stock Price

Thor Medical A Price

Frankfurt·CLOSED
5.86NOK+0.43 (+7.62 %)
Market closed

Revenue has compounded at 15.0% per year over the past 5 years to 302,000.00 NOK. Thor Medical A's net margin stands at -97,289.4%, down from -5,487.1% several years earlier. Analysts set a median price target of 5.10 NOK, implying 13.0% below the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 145% above its 52-week low.

Thor Medical A stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Thor Medical A over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Thor Medical A stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Thor Medical A's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Thor Medical A Stock Price History
DateThor Medical A Price
8/10/20265.86 NOK
8/7/20265.43 NOK
8/6/20265.30 NOK
8/5/20265.55 NOK
8/4/20265.23 NOK
7/31/20265.79 NOK
7/30/20264.43 NOK
7/29/20264.45 NOK
7/28/20264.49 NOK
7/27/20264.44 NOK
7/24/20264.44 NOK
7/23/20264.39 NOK
7/22/20264.39 NOK
7/21/20264.34 NOK
7/20/20264.26 NOK
7/17/20264.29 NOK
7/16/20264.26 NOK
7/15/20264.33 NOK
7/14/20264.28 NOK
7/13/20264.16 NOK
7/10/20264.19 NOK
7/9/20264.30 NOK
7/8/20264.30 NOK
7/7/20264.34 NOK
7/6/20264.36 NOK
7/3/20264.48 NOK
7/2/20264.39 NOK
7/1/20264.24 NOK
6/30/20264.28 NOK
6/29/20264.32 NOK
6/26/20264.25 NOK
6/25/20264.43 NOK
6/24/20264.36 NOK
6/23/20264.24 NOK
6/22/20264.22 NOK
6/19/20264.20 NOK
6/18/20264.07 NOK
6/17/20264.03 NOK
6/16/20264.05 NOK
6/15/20264.30 NOK
6/12/20264.18 NOK
6/11/20263.96 NOK
6/10/20264.03 NOK
6/9/20264.06 NOK
6/8/20264.11 NOK
6/5/20264.14 NOK
6/4/20264.22 NOK
6/3/20264.34 NOK
6/2/20264.37 NOK
6/1/20264.45 NOK
5/29/20264.64 NOK
5/28/20264.61 NOK
5/27/20264.51 NOK
5/26/20264.51 NOK
5/22/20264.53 NOK
5/21/20264.51 NOK
5/20/20264.41 NOK
5/19/20264.30 NOK
5/18/20264.39 NOK
5/15/20264.43 NOK
5/13/20264.41 NOK
5/12/20264.47 NOK
5/11/20264.49 NOK
5/8/20264.41 NOK
5/7/20264.45 NOK
5/6/20264.49 NOK
5/5/20264.40 NOK
5/4/20264.48 NOK
4/30/20264.43 NOK
4/29/20264.25 NOK
4/28/20264.80 NOK
4/27/20264.79 NOK
4/24/20264.82 NOK
4/23/20264.86 NOK
4/22/20264.91 NOK
4/21/20265.10 NOK
4/20/20265.05 NOK
4/17/20265.01 NOK
4/16/20264.95 NOK
4/15/20265.03 NOK
4/14/20264.89 NOK
4/13/20265.26 NOK
4/10/20265.45 NOK
4/9/20265.58 NOK
4/8/20265.21 NOK
4/7/20264.93 NOK
4/1/20264.89 NOK
3/31/20264.59 NOK
3/30/20264.43 NOK
3/27/20264.53 NOK
3/26/20264.51 NOK
3/25/20264.69 NOK
3/24/20264.55 NOK
3/23/20264.60 NOK
3/20/20264.59 NOK
3/19/20264.63 NOK
3/18/20264.90 NOK
3/17/20264.73 NOK
3/16/20264.56 NOK
3/13/20264.68 NOK
3/12/20264.63 NOK
3/11/20264.32 NOK
3/10/20264.36 NOK
3/9/20264.20 NOK
3/6/20264.25 NOK
3/5/20264.49 NOK
3/4/20264.07 NOK
3/3/20264.17 NOK
3/2/20264.03 NOK
2/27/20264.26 NOK
2/26/20264.63 NOK
2/25/20264.44 NOK
2/24/20264.51 NOK
2/23/20264.20 NOK
2/20/20264.38 NOK
2/19/20264.38 NOK
2/18/20264.20 NOK
2/17/20264.26 NOK
2/16/20265.18 NOK
2/13/20265.11 NOK
2/12/20265.29 NOK
2/11/20265.40 NOK
2/10/20265.11 NOK
2/9/20264.99 NOK
2/6/20264.76 NOK
2/5/20264.60 NOK
2/4/20264.80 NOK
2/3/20264.77 NOK
2/2/20264.75 NOK
1/30/20264.86 NOK
1/29/20264.93 NOK
1/28/20265.03 NOK
1/27/20265.11 NOK
1/26/20265.01 NOK
1/23/20265.13 NOK
1/22/20265.08 NOK
1/21/20264.66 NOK
1/20/20264.86 NOK
1/19/20264.84 NOK
1/16/20264.93 NOK
1/15/20264.88 NOK
1/14/20264.85 NOK
1/13/20265.00 NOK
1/12/20265.11 NOK
1/9/20265.17 NOK
1/8/20265.09 NOK
1/7/20265.19 NOK
1/6/20265.22 NOK
1/5/20265.05 NOK
1/2/20265.01 NOK
12/30/20255.25 NOK
12/29/20255.26 NOK
12/23/20255.15 NOK
12/22/20254.82 NOK
12/19/20254.51 NOK
12/18/20254.31 NOK
12/17/20254.34 NOK
12/16/20254.22 NOK
12/15/20254.19 NOK
12/12/20254.11 NOK
12/11/20254.13 NOK
12/10/20254.09 NOK
12/9/20254.04 NOK
12/8/20254.11 NOK
12/5/20254.22 NOK
12/4/20254.25 NOK
12/3/20254.10 NOK
12/2/20254.35 NOK
12/1/20254.39 NOK
11/28/20254.49 NOK
11/27/20254.34 NOK
11/26/20254.14 NOK
11/25/20253.99 NOK
11/24/20253.74 NOK
11/21/20253.69 NOK
11/20/20253.73 NOK
11/19/20253.52 NOK
11/18/20253.51 NOK
11/17/20253.58 NOK
11/14/20253.61 NOK
11/13/20253.71 NOK
11/12/20253.70 NOK
11/11/20253.63 NOK
11/10/20253.62 NOK
11/7/20253.61 NOK
11/6/20253.70 NOK
11/5/20253.53 NOK
11/4/20253.77 NOK
11/3/20253.85 NOK
10/31/20253.57 NOK
10/30/20253.35 NOK
10/29/20253.48 NOK
10/28/20253.50 NOK
10/27/20253.49 NOK
10/24/20253.55 NOK
10/23/20253.51 NOK
10/22/20253.49 NOK
10/21/20253.50 NOK
10/20/20253.56 NOK
10/17/20253.58 NOK
10/16/20253.63 NOK
10/15/20253.63 NOK
10/14/20253.50 NOK
10/13/20253.49 NOK
10/10/20253.53 NOK
10/9/20253.57 NOK
10/8/20253.53 NOK
10/7/20253.58 NOK
10/6/20253.60 NOK
10/3/20253.75 NOK
10/2/20253.55 NOK
10/1/20253.52 NOK
9/30/20253.27 NOK
9/29/20253.41 NOK
9/26/20253.65 NOK
9/25/20253.57 NOK
9/24/20253.60 NOK
9/23/20253.69 NOK
9/22/20253.87 NOK
9/19/20254.36 NOK
9/18/20254.44 NOK
9/17/20254.68 NOK
9/16/20254.70 NOK
9/15/20254.28 NOK
9/12/20254.06 NOK
9/11/20253.96 NOK
9/10/20253.86 NOK
9/9/20253.69 NOK
9/8/20253.60 NOK
9/5/20253.60 NOK
9/4/20253.61 NOK
9/3/20253.33 NOK
9/2/20253.30 NOK
9/1/20253.48 NOK
8/29/20253.20 NOK
8/28/20252.88 NOK
8/27/20252.94 NOK
8/26/20252.87 NOK
8/25/20252.78 NOK
8/22/20252.72 NOK
8/21/20252.70 NOK
8/20/20252.59 NOK
8/19/20252.71 NOK
8/18/20252.81 NOK
8/15/20252.60 NOK
8/14/20252.51 NOK
8/13/20252.39 NOK
Access this data via the Eulerpool API
Get Free API Key

Thor Medical A Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
0.00 NOK
-442.43 M NOK
-441.30 M NOK
Jan 1, 2022
0.00 NOK
-317.36 M NOK
-311.24 M NOK
Jan 1, 2023
0.00 NOK
-7.20 M NOK
-26.56 M NOK
Jan 1, 2025 (e)
3.00 M NOK
1.80 M NOK
-88.52 M NOK
Jan 1, 2026 (e)
49.00 M NOK
29.40 M NOK
-49.57 M NOK
Jan 1, 2027 (e)
168.00 M NOK
100.80 M NOK
-38.95 M NOK
Jan 1, 2028 (e)
184.00 M NOK
110.40 M NOK
-24.79 M NOK
Jan 1, 2029 (e)
604.00 M NOK
362.40 M NOK
70.82 M NOK

Thor Medical A Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 1:07 AM
 
REVENUEM NOK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM NOK
EBITM NOK
EBIT MARGIN%
NET INCOMEM NOK
NET INCOME GROWTH%
SHARESM
201320142015201620172018201920202021202220232025e2026e2027e2028e2029e
–––––––––––3.0049.00168.00184.00604.00
––––––––––––1,533.33242.869.52228.26
–––––––––––-7,400.00-453.06-132.14-120.65-36.75
-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00-222.00
-18.00-68.00-183.00-216.00-316.00-340.00-440.00-434.00-442.00-317.00-7.001.0029.00100.00110.00362.00
–––––––––––33.3359.1859.5259.7859.93
-17.00-63.00-173.00-235.00-293.00-337.00-433.00-417.00-441.00-311.00-26.00-88.00-49.00-38.00-24.0070.00
30.77270.59174.6035.8424.6815.0228.49-3.705.76-29.48-91.64238.46-44.32-22.45-36.84-391.67
9.0218.3241.25174.79174.79174.79174.79174.79174.79116.04174.79174.79174.79174.79174.79174.79
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Thor Medical A generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Thor Medical A retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Thor Medical A's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Thor Medical A has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Thor Medical A's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Thor Medical A stock margins

The Thor Medical A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Thor Medical A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Thor Medical A.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
60.00 %
-2,950.67 %
Jan 1, 2026 (e)
0.00 %
60.00 %
-101.17 %
Jan 1, 2027 (e)
0.00 %
60.00 %
-23.18 %

Thor Medical A Stock Revenue, EBIT, Earnings per Share

The Thor Medical A earnings per share therefore indicates how much revenue Thor Medical A has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 NOK
0.00 NOK
0.00 NOK
Jan 1, 2020
0.00 NOK
0.00 NOK
0.00 NOK
Jan 1, 2021
0.00 NOK
0.00 NOK
0.00 NOK
Jan 1, 2022
0.00 NOK
-2.74 NOK
-2.68 NOK
Jan 1, 2023
0.00 NOK
-0.04 NOK
-0.15 NOK
Jan 1, 2025 (e)
0.01 NOK
0.01 NOK
-0.25 NOK
Jan 1, 2026 (e)
0.14 NOK
0.17 NOK
-0.14 NOK
Jan 1, 2027 (e)
0.47 NOK
0.58 NOK
-0.11 NOK

Thor Medical A business model & stock analysis

Nordic Nanovector ASA is a Norwegian biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of lymphoma and other cancers. The company was founded in 2009 by a group of leading scientists in the field of cancer research, focused on developing new and innovative treatment options for cancer. Nordic Nanovector's business model is based on the use of antibodies specifically targeted to cancer cells. An example of this is the drug Betalutin, which contains a radioactive substance that selectively destroys cancer cells. Betalutin has been tested in multiple clinical trials and has shown promising results in the treatment of non-Hodgkin lymphoma. In addition to Betalutin, the company also has another technology platform based on the use of antibodies with high affinity to specific types of cancer. Nordic Nanovector also manufactures a wide range of diagnostic tools that can be used in cancer research. Since its inception, Nordic Nanovector has received numerous national and international awards and prizes for its innovative products and technologies. The company has established relationships with various academic institutions and organizations to advance research and development. In addition to product development, the company has undergone an impressive capital raise to advance the development of these therapies. Nordic Nanovector has received several public and private financings in recent years to support and expand its research activities. In 2015, the company went public on the Oslo Stock Exchange, foregoing the conquest of the US market. The foundation of the company's portfolio is protected by technology patents and product patents. The company has undergone several challenging development and approval steps to gain a competitive advantage over competitors. The goal is to promote long-term growth and availability of the products worldwide. Nordic Nanovector believes that its business model is realized based on innovative technologies in cancer research. With a focus on the development of therapies and diagnostic tools, the company has built significant potential in the industry. The future prospects and growth outlook are positive and are expected to contribute to even greater success for Nordic Nanovector in the future.

Thor Medical A SWOT Analysis

Strengths

Nordic Nanovector ASA possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of innovative products and technologies in the field of targeted therapeutics for cancer treatment. This allows Nordic Nanovector ASA to differentiate itself from competitors and attract potential customers.

Secondly, the company has a highly skilled and experienced team of researchers, scientists, and professionals who contribute to the development and advancement of its product pipeline. This expertise enables Nordic Nanovector ASA to maintain a high level of quality and efficiency in its research and development processes.

Lastly, Nordic Nanovector ASA enjoys a solid financial position, with sufficient capital reserves to fund its operations and strategic initiatives. This financial stability provides the company with a competitive edge and enables it to invest in growth opportunities and expand its market presence.

Weaknesses

However, Nordic Nanovector ASA also faces certain weaknesses that may hinder its growth and competitive position. One major weakness is the company's heavy reliance on a limited number of product candidates. If any of these candidates fail to meet regulatory or clinical trial requirements, it may significantly impact the company's revenue stream and overall performance.

In addition, Nordic Nanovector ASA currently lacks a diversified product portfolio, which makes the company more vulnerable to market fluctuations and changes in customer preferences. The absence of alternative revenue streams puts the company at risk of relying too heavily on the success of a few key products.

Opportunities

Despite its weaknesses, Nordic Nanovector ASA has several opportunities to capitalize on and enhance its market position. Firstly, the increasing prevalence of cancer globally presents a significant opportunity for the company to address unmet medical needs and expand its customer base.

Furthermore, partnerships and collaborations with other pharmaceutical companies or research institutions provide Nordic Nanovector ASA with opportunities to access additional resources, knowledge, and expertise. Such collaborations can accelerate the development and commercialization of the company's products, ultimately strengthening its competitive advantage.

Threats

Nordic Nanovector ASA also faces certain threats that could potentially impact its performance and market position. One significant threat is the intense competition within the pharmaceutical industry. The presence of established competitors with similar products and technologies may limit the company's market share and profitability.

Another threat is the stringent regulatory requirements and approval processes imposed by regulatory authorities. Any delays or failures in obtaining necessary approvals can significantly impede the company's ability to bring its products to market in a timely manner and generate revenue.

Thor Medical A Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Thor Medical A historical P/E ratio, EBIT multiple, and P/S ratio

Thor Medical A annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Thor Medical A shares outstanding

The number of shares of Thor Medical A was 174.79 M in 2025. This indicates how many shares Thor Medical A is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
41.25 M Stocks
Jan 1, 2020
41.25 M Stocks
Jan 1, 2021
41.25 M Stocks
Jan 1, 2022
116.04 M Stocks
Jan 1, 2023
174.79 M Stocks
Jan 1, 2025 (e)
174.79 M Stocks
Jan 1, 2026 (e)
174.79 M Stocks
Jan 1, 2027 (e)
174.79 M Stocks

Current Thor Medical A forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
5.10
Last Price
5.86
Currency
NOK
12M Return Potential
-12.97 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Thor Medical A stock

35/100
36
Environment
51
Social
18
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Thor Medical A shareholder structure

% Name
0.07566%
Storebrand Kapitalforvaltning AS
Storebrand Kapitalforvaltning AS
0.04662%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.00074%
State Street Global Advisors (US)
State Street Global Advisors (US)

Thor Medical A Beneficial Ownership Filings (SEC 13D/G)

Free Float
28.5%
Float Shares
-
Shares Outstanding
-

Thor Medical A Executives and Management Board

8 members · avg. age 59 · 25 % women

SH

Dr. Sindre Hassfjell

Chief Technology Officer

2.77 M NOK

Management

BE

Mr. Brede Ellingsaeter (36)

Chief Financial and Operating Officer

2.36 M NOK
AL

Ms. Astrid Liland

Vice President - HSEQ

2.35 M NOK
JK

Mr. Jasper Kurth (40)

Chief Executive Officer

2.02 M NOK
AB

Dr. Alf Bjornseth (83)

Executive Vice President - Business Development

1.80 M NOK

Board of Directors

LS

Mr. Ludvik Sandnes (75)

Independent Chairman of the Board · since 2013

350,000.00 NOK
JA

Mr. John Andersen

Director

350,000.00 NOK
MB

Ms. Mimi Berdal

Independent Director

350,000.00 NOK

Frequently asked questions about Thor Medical A

The business model of Nordic Nanovector ASA focuses on the development and commercialization of targeted therapies for hematological cancers. The company specializes in the development of innovative antibody-radionuclide conjugates (ARCs), which deliver highly specific radiation directly to cancer cells. By targeting and effectively treating cancers such as non-Hodgkin’s lymphoma, Nordic Nanovector aims to improve patient outcomes and quality of life. The company’s dedication to research, development, and commercialization of novel therapies places it at the forefront of the fight against hematological cancers, making Nordic Nanovector a prominent player in the biotechnology industry.

Nordic Nanovector ASA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Nordic Nanovector ASA in the market are other companies operating in the field of targeted therapies for cancer treatment. However, Nordic Nanovector ASA maintains a unique position due to its innovative technology and product pipeline. With its lead candidate, Betalutin®, Nordic Nanovector ASA aims to provide a superior treatment option for patients suffering from non-Hodgkin's lymphoma. Despite facing competition, Nordic Nanovector ASA's strategic focus and ongoing advancements position it as a prominent player in the market.

Nordic Nanovector ASA is a biopharmaceutical company based in Norway. Founded in 2009, the company focuses on the development and commercialization of innovative targeted therapeutics for the treatment of hematological malignancies. Nordic Nanovector's flagship product candidate is Betalutin®, a novel radioimmunotherapy designed to improve patient outcomes in non-Hodgkin lymphoma. With a strong background in radioimmunotherapy and precision medicine, Nordic Nanovector aims to revolutionize cancer treatment by delivering more effective and less toxic therapies. Through strategic collaborations and continuous research and development efforts, the company strives to advance the field of precision oncology and bring hope to patients worldwide. Nordic Nanovector ASA continues to pursue its mission of improving cancer care and addressing unmet medical needs.

Nordic Nanovector ASA, a leading biotechnology company, has achieved several significant milestones. The company successfully completed the phase 1 clinical trial for its innovative targeted therapy, Betalutin, designed for the treatment of non-Hodgkin lymphoma (NHL). Furthermore, Nordic Nanovector ASA received Fast Track designation from the U.S. FDA for Betalutin, recognizing its potential to address unmet medical needs. The company also secured Orphan Drug Designation for Betalutin from both the FDA and the European Medicines Agency (EMA), providing further regulatory support. These achievements highlight Nordic Nanovector ASA's commitment to developing groundbreaking therapies and solidify its position as a key player in the field of oncology.

Nordic Nanovector ASA primarily operates in Norway, as it is a Norwegian biopharmaceutical company. However, the company's presence is not limited to Norway alone. Nordic Nanovector ASA has expanded its reach to other countries and regions as well, including the United States, throughout Europe, and Asia. With its focus on developing innovative targeted therapies for hematological cancers, Nordic Nanovector ASA is continuously seeking to collaborate with global partners and extend its presence in key markets worldwide.

Nordic Nanovector ASA represents a set of core values and a corporate philosophy that guides its operations. The company believes in innovation, scientific excellence, and a patient-centered approach. Nordic Nanovector is dedicated to developing targeted therapies for patients with hematological malignancies, aiming to improve their quality of life and overall survival. By leveraging its proprietary technology platform, the company aims to make a meaningful impact in the field of precision medicine. Nordic Nanovector ASA strives to collaborate with partners and stakeholders to accelerate the development of novel treatments and bring hope to patients in need.

Analysts currently set an average price target of 5.10 NOK for the Thor Medical A stock (median: 5.10 NOK), implying -13.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Thor Medical A Analyst Price Targets 2026

9 analysts currently rate the Thor Medical A stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Thor Medical A to generate revenue of 49.00 M NOK and earnings per share of -0.28 NOK.

Thor Medical A Analyst Price Targets 2026

Converted at the current exchange rate, the Thor Medical A share trades at 0.53 EUR (5.86 NOK).

The Thor Medical A share (TRMED.OL) is listed on 5 stock exchanges, including: Frankfurt (8NN.F), München (8NN.MU), Düsseldorf (8NN.DU), London (0R6Y.L), SIX (Zürich) (8NN.SW).

Nordic Nanovector ASA is a Norwegian company specializing in the development of innovative therapies for the treatment of non-Hodgkin lymphomas. The company operates with a unique business model based on scientific research and strategic partnerships. The company focuses on the development of innovative antibody therapies that target specific antigens of non-Hodgkin lymphomas. They also developed Betalutin®, a radioisotope-based conjugate that aims to selectively destroy cancer cells. Nordic Nanovector ASA works closely with strategic partners to advance the development and commercialization of its products, aiming to reduce costs and risks while increasing the reach and success of its products. In summary, Nordic Nanovector ASA develops innovative antibody therapies and radioisotope-based conjugates to fight non-Hodgkin lymphomas, working with strategic partners to drive product development and commercialization, and pursuing a research strategy focused on scientific excellence and long-term success.

The expected revenue of Thor Medical A is 49.00 M NOK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Thor Medical A is -49.57 M NOK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Thor Medical A is currently -20.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Thor Medical A stock.

The price-to-sales ratio (P/S) of Thor Medical A is currently 20.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Thor Medical A stock.

The Eulerpool Quality Score for Thor Medical A is 1/10.

The ISIN of Thor Medical A is NO0010597883. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Thor Medical A is A1H64K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Thor Medical A is TRMED.OL. The ticker symbol is used to trade Thor Medical A shares on the stock exchange.

Thor Medical A paid dividends every year for the past 0 years.

Thor Medical A is assigned to the 'Health' sector.

The dividends of Thor Medical A are distributed in NOK.

All fundamentals and in-depth analysis of Thor Medical A

Our stock analysis for Thor Medical A stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Thor Medical A. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Thor Medical A Stock
Thor Medical A Revenue→
Thor Medical A Stock
Thor Medical A Net Income→
Thor Medical A Stock
Thor Medical A P/E→
Thor Medical A Stock
Thor Medical A P/S→
Thor Medical A Stock
Thor Medical A EBIT→
Thor Medical A Stock
Thor Medical A Dividend→
Thor Medical A Stock
Thor Medical A Directors Dealings→
Thor Medical A Stock
Thor Medical A Stocks→
Thor Medical A Stock
Thor Medical A Market capitalization→
Thor Medical A Stock
Thor Medical A Debt→
Thor Medical A Stock
Thor Medical A Liabilities→
Thor Medical A Stock
Thor Medical A Equity→
Thor Medical A Stock
Thor Medical A AAQS→
Thor Medical A Stock
Thor Medical A Employees→
Thor Medical A Stock
Thor Medical A ROE→
Thor Medical A Stock
Thor Medical A ROA→
Thor Medical A Stock
Thor Medical A ROCE→
Thor Medical A Stock
Thor Medical A News→
Thor Medical A Stock
Thor Medical A Analyst Price Targets→

Health Stocks

Thyrocare TechnologiesThonburi Medical Centre PCLTianjin Chase Sun Pharmaceutical CoThonburi Healthcare Group PCLTianjin Lisheng Pharmaceutical CoThomson Medical GroupTianjin Pharmaceutical Da Ren Tang Group CorpThird Age Health ServicesTianjin Ringpu Bio-Technology CoThermogenesis HoldingsTiansheng Pharmaceutical Group CoThermo Fisher ScientificAll Stocks A–Z →